1.Meta-analysis of Platelet Lymphocyte Ratio as A Prognostic Factor for Non-small Cell Lung Cancer.
Haoran CHEN ; Hao XUE ; Wenjing LIU ; Fangfang WU ; Yituo WANG ; Hongjun GAO
Chinese Journal of Lung Cancer 2019;22(5):289-298
		                        		
		                        			BACKGROUND:
		                        			Current research shows that platelet to lymphocyte ratio (PLR) has important prognostic value in renal cell carcinoma, esophageal cancer, gastric cancer, liver cancer and colon cancer. The aim of the study is to evaluate the prognostic value of PLR in non-small cell lung cancer (NSCLC) through meta-analysis.
		                        		
		                        			METHODS:
		                        			Literature search for PubMed, EMBASE, Web of Science, Medline, Cochrane Library, China National Knowledge Internet (CNKI), China Biomedical Medicine disc (CBMdisc), VIP, Wanfang Database using computer electronic system to study the association between PLR and overall survival (OS) and disease-free survival (DFS). Each eligible study data is extracted and a meta-analysis is performed using the hazard risk (HR) and 95% confidence interval (95%CI) to assess the prognostic value of PLR, the time limit for the search is to build the library until November 2018.
		                        		
		                        			RESULTS:
		                        			We include a total of 15 research literatures involving 5,524 patients for meta-analysis. According to the results of the meta-analysis: The OS of the higher PLR group is significantly lower than that of the lower PLR group (HR=1.69, 95%CI: 1.45-1.97, P<0.000,01, I²=46.2%, Pheterogeneity=0.026); the DFS of the higher PLR group is significantly lower than that of the lower PLR group (HR=1.41, 95%CI: 1.14-1.74, P=0.001, I²=46.2%, Pheterogeneity=0.026). Subgroup analysis show that the OS of the higher PLR group is still significantly lower than the lower PLR group (P<0.05) after grouping by ethnicity, sample size, PLR cutoff value and treatment.
		                        		
		                        			CONCLUSIONS
		                        			Increased PLR is associated with poor prognosis in NSCLC, so PLR may be an important biological predictive marker for NSCLC patients, however, its clinical application still needs to be verified through more research in the future.
		                        		
		                        		
		                        		
		                        			Blood Platelets
		                        			;
		                        		
		                        			cytology
		                        			;
		                        		
		                        			Carcinoma, Non-Small-Cell Lung
		                        			;
		                        		
		                        			blood
		                        			;
		                        		
		                        			diagnosis
		                        			;
		                        		
		                        			pathology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lung Neoplasms
		                        			;
		                        		
		                        			blood
		                        			;
		                        		
		                        			diagnosis
		                        			;
		                        		
		                        			pathology
		                        			;
		                        		
		                        			Lymphocytes
		                        			;
		                        		
		                        			cytology
		                        			;
		                        		
		                        			Platelet Count
		                        			;
		                        		
		                        			Prognosis
		                        			
		                        		
		                        	
2.Current Pathological and Laboratory Considerations in the Diagnosis of Disseminated Intravascular Coagulation.
Cheng Hock TOH ; Yasir ALHAMDI ; Simon T ABRAMS
Annals of Laboratory Medicine 2016;36(6):505-512
		                        		
		                        			
		                        			Systemically sustained thrombin generation in vivo is the hallmark of disseminated intravascular coagulation (DIC). Typically, this is in response to a progressing disease state that is associated with significant cellular injury. The etiology could be infectious or noninfectious, with the main pathophysiological mechanisms involving cross-activation among coagulation, innate immunity, and inflammatory responses. This leads to consumption of both pro- and anticoagulant factors as well as endothelial dysfunction and disrupted homeostasis at the blood vessel wall interface. In addition to the release of tissue plasminogen activator (tPA) and soluble thrombomodulin (sTM) following cellular activation and damage, respectively, there is the release of damage-associated molecular patterns (DAMPs) such as extracellular histones and cell-free DNA. Extracellular histones are increasingly recognized as significantly pathogenic in critical illnesses through direct cell toxicity, the promotion of thrombin generation, and the induction of neutrophil extracellular trap (NET) formation. Clinically, high circulating levels of histones and histone–DNA complexes are associated with multiorgan failure, DIC, and adverse patient outcomes. Their measurements as well as that of other DAMPs and molecular markers of thrombin generation are not yet applicable in the routine diagnostic laboratory. To provide a practical diagnostic tool for acute DIC, a composite scoring system using rapidly available coagulation tests is recommended by the International Society on Thrombosis and Haemostasis. Its usefulness and limitations are discussed alongside the advances and unanswered questions in DIC pathogenesis.
		                        		
		                        		
		                        		
		                        			Blood Platelets/cytology/pathology
		                        			;
		                        		
		                        			Disseminated Intravascular Coagulation/*diagnosis/pathology
		                        			;
		                        		
		                        			Fibrin Fibrinogen Degradation Products/analysis
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunity, Innate
		                        			;
		                        		
		                        			Laboratories, Hospital
		                        			;
		                        		
		                        			Partial Thromboplastin Time
		                        			;
		                        		
		                        			Prothrombin Time
		                        			;
		                        		
		                        			Thrombelastography
		                        			
		                        		
		                        	
3.Magnetization-tagged MRI is a simple method for predicting liver fibrosis.
Kyung Eun KIM ; Mi Suk PARK ; Sohae CHUNG ; Chansik AN ; Leon AXEL ; Rakhmonova Gulbahor ERGASHOVNA
Clinical and Molecular Hepatology 2016;22(1):140-145
		                        		
		                        			
		                        			BACKGROUND/AIMS: To assess the usefulness of magnetization-tagged magnetic resonance imaging (MRI) in quantifying cardiac-induced liver motion and deformation in order to predict liver fibrosis. METHODS: This retrospective study included 85 patients who underwent liver MRI including magnetization-tagged sequences from April 2010 to August 2010. Tagged images were acquired in three coronal and three sagittal planes encompassing both the liver and heart. A Gabor filter bank was used to measure the maximum value of displacement (MaxDisp) and the maximum and minimum values of principal strains (MaxP1 and MinP2, respectively). Patients were divided into three groups (no fibrosis, mild-to-moderate fibrosis, and significant fibrosis) based on their aspartate-aminotransferase-to-platelet ratio index (APRI) score. Group comparisons were made using ANOVA tests. RESULTS: The patients were divided into three groups according to APRI scores: no fibrosis (≤0.5; n=41), moderate fibrosis (0.5-1.5; n=23), and significant fibrosis (>1.5; n=21). The values of MaxDisp were 2.9±0.9 (mean±SD), 2.3±0.7, and 2.1±0.6 in the no fibrosis, moderate fibrosis, and significant fibrosis groups, respectively (P<0.001); the corresponding values of MaxP1 were 0.05±0.2, 0.04±0.02, and 0.03±0.01, respectively (P=0.002), while those of MinP2 were -0.07±0.02, -0.05±0.02, and -0.04±0.01, respectively (P<0.001). CONCLUSIONS: Tagged MRI to quantify cardiac-induced liver motion can be easily incorporated in routine liver MRI and may represent a helpful complementary tool in the diagnosis of early liver fibrosis.
		                        		
		                        		
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aspartate Aminotransferases/analysis
		                        			;
		                        		
		                        			Blood Platelets/cytology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Liver Cirrhosis/*diagnostic imaging/metabolism/pathology
		                        			;
		                        		
		                        			*Magnetic Resonance Imaging
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Severity of Illness Index
		                        			
		                        		
		                        	
4.Prognostic Significance of Initial Platelet Counts and Fibrinogen Level in Advanced Non-Small Cell Lung Cancer.
Kyung Hee KIM ; Tae Yun PARK ; Ji Yeun LEE ; Sang Min LEE ; Jae Joon YIM ; Chul Gyu YOO ; Young Whan KIM ; Sung Koo HAN ; Seok Chul YANG
Journal of Korean Medical Science 2014;29(4):507-511
		                        		
		                        			
		                        			Thrombocytosis and coagulation systems activation are commonly associated with disease progression and are suggested poor prognostic factors in patients with malignancies. This study aimed to investigate the prevalence and prognostic significance of thrombocytosis and elevated fibrinogen levels in patients with advanced non-small cell lung cancer (NSCLC). Initial platelet counts and fibrinogen levels were reviewed in 854 patients with histologically proven NSCLC. Thrombocytosis was defined as platelet counts > 450 x 10(9)/L. A serum fibrinogen level > 4.5 g/L was considered high. At the time of diagnosis, initial platelet counts and serum fibrinogen levels were evaluated before treatment. Clinicopathologic data including histological type, tumor, node, metastasis (TNM) stage, performance status, treatment method, and survival time were evaluated. Initial thrombocytosis was found in 6.9% of patients, and elevated fibrinogen levels were found in 55.1% of patients. Patients with thrombocytosis had a significantly poorer prognosis than patients with normal platelet counts (P < 0.001). In multivariate survival analysis, thrombocytosis was an independent prognostic factor (P < 0.001). An elevated serum fibrinogen level was associated with poor prognosis (P < 0.001). In conclusion, initial thrombocytosis and a high fibrinogen level are independent factors for predicting poor prognosis in patients with advanced NSCLC.
		                        		
		                        		
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Blood Platelets/*cytology
		                        			;
		                        		
		                        			Carcinoma, Non-Small-Cell Lung/*diagnosis/mortality/pathology
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Fibrinogen/*analysis
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lung Neoplasms/*diagnosis/mortality/pathology
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Neoplasm Staging
		                        			;
		                        		
		                        			Platelet Count
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Survival Rate
		                        			;
		                        		
		                        			Thrombocytosis/complications/diagnosis
		                        			
		                        		
		                        	
5.Cell Therapy for Wound Healing.
Journal of Korean Medical Science 2014;29(3):311-319
		                        		
		                        			
		                        			In covering wounds, efforts should include utilization of the safest and least invasive methods with goals of achieving optimal functional and cosmetic outcome. The recent development of advanced wound healing technology has triggered the use of cells to improve wound healing conditions. The purpose of this review is to provide information on clinically available cell-based treatment options for healing of acute and chronic wounds. Compared with a variety of conventional methods, such as skin grafts and local flaps, the cell therapy technique is simple, less time-consuming, and reduces the surgical burden for patients in the repair of acute wounds. Cell therapy has also been developed for chronic wound healing. By transplanting cells with an excellent wound healing capacity profile to chronic wounds, in which wound healing cannot be achieved successfully, attempts are made to convert the wound bed into the environment where maximum wound healing can be achieved. Fibroblasts, keratinocytes, adipose-derived stromal vascular fraction cells, bone marrow stem cells, and platelets have been used for wound healing in clinical practice. Some formulations are commercially available. To establish the cell therapy as a standard treatment, however, further research is needed.
		                        		
		                        		
		                        		
		                        			Blood Platelets/metabolism
		                        			;
		                        		
		                        			Cell- and Tissue-Based Therapy
		                        			;
		                        		
		                        			Diabetes Mellitus, Type 2/complications/pathology
		                        			;
		                        		
		                        			Fibroblasts/cytology/transplantation
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Keratinocytes/cytology/transplantation
		                        			;
		                        		
		                        			Stromal Cells/cytology/transplantation
		                        			;
		                        		
		                        			Tissue Engineering
		                        			;
		                        		
		                        			Ulcer/etiology/therapy
		                        			;
		                        		
		                        			*Wound Healing
		                        			
		                        		
		                        	
6.Mean Platelet Volume and Vitamin D Level.
Medine CUMHUR CURE ; Erkan CURE ; Suleyman YUCE ; Tarkan YAZICI ; Inanc KARAKOYUN ; Hasan EFE
Annals of Laboratory Medicine 2014;34(2):98-103
		                        		
		                        			
		                        			BACKGROUND: Vitamin D deficiency and a high mean platelet volume (MPV) are related to cardiovascular disease. We investigated whether vitamin D deficiency is associated with high MPV. METHODS: This study included 434 patients without chronic disease who were not taking vitamin D or calcium supplements. Vitamin D was measured by chemiluminescent microparticle immunoassay on the Architect-I2000 system (Abbott Diagnostics, USA), and MPV was measured on the Cell-Dyn Ruby analyzer (Abbott Diagnostics). Patients were divided into Groups 1 (138 [men/women, 46/92]), 2 (148 [men/women, 54/94]), and 3 (148 [men/women, 50/98]) according to vitamin D levels of <10 ng/mL, 10-20 ng/mL, and >20 ng/mL, respectively. RESULTS: The vitamin D level in Group 1 (7.7+/-1.9 ng/mL) was lower than that in Group 2 (15.1+/-1.6 ng/mL, P<0.001) and Group 3 (25.6+/-6.3 ng/mL, P<0.001). The MPV in Group 3 (7.5+/-1.0 fL) was lower than that in Group 1 (8.1+/-1.1 fL, P<0.001) and Group 2 (7.9+/-1.0 fL, P=0.009). Linear regression analysis showed that low levels of vitamin D (beta=-0.109, P=0.019) was independently associated with increased MPV. CONCLUSIONS: There was a strong association between a low vitamin D level and a high MPV; therefore, vitamin D deficiency may be associated with increased MPV.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Age Factors
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Blood Glucose/analysis
		                        			;
		                        		
		                        			Blood Platelets/*cytology
		                        			;
		                        		
		                        			Cell Size
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunoassay
		                        			;
		                        		
		                        			Luminescent Measurements
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Vitamin D/*analysis
		                        			;
		                        		
		                        			Vitamin D Deficiency/metabolism/pathology
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
7.Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients.
Hyun Seok LEE ; Young Oh KWEON ; Won Young TAK ; Soo Young PARK ; Eun Jung KANG ; Yu Lim LEE ; Hae Min YANG ; Hyun Woo PARK
Clinical and Molecular Hepatology 2013;19(2):148-155
		                        		
		                        			
		                        			BACKGROUND/AIMS: Chronic hepatitis C patients with advanced fibrosis have unsatisfactory sustained virological response (SVR) rates. Few data demonstrating the efficacy of combination therapy in chronic hepatitis C patients with advanced fibrosis in South Korea are available. The purpose of this study was to assess whether the stage of fibrosis impacts the efficacy of combination therapy for chronic hepatitis C. METHODS: We retrospectively reviewed data for a total of 109 patients with chronic hepatitis C, treated with peginterferon alfa and ribavirin. SVR according to the stage of liver fibrosis assessed by pretreatment liver biopsy and genotype results were analyzed. RESULTS: Data from 66 genotype 1 patients (60.6%) and 43 genotype 2 or 3 patients (39.4%) among the 109 patients were analyzed. SVR rates for the genotype 1 patients were significantly lower for the stage 3-4 group (32.1%) than the stage 0-2 group (78.9%; P<0.001). SVR rates (92.0% for stage 0-2, 77.8% for stage 3-4, P=0.184) of genotype 2 or 3 patients were not significantly different according to fibrosis stage. Likewise, the frequency of adverse events was not significantly different according to fibrosis stage. CONCLUSIONS: Compared to patients without advanced fibrosis, we can anticipate good SVR rates for genotype 2 or 3 patients with advanced fibrosis and they did not show an inferior tolerability for peginterferon and ribavirin combination therpy. Our results suggest that active treatment is needed for genotype 2 or 3 patients with advanced fibrosis.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Age Factors
		                        			;
		                        		
		                        			Antiviral Agents/therapeutic use
		                        			;
		                        		
		                        			Blood Platelets/cytology
		                        			;
		                        		
		                        			Drug Therapy, Combination
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Genotype
		                        			;
		                        		
		                        			Hepacivirus/genetics
		                        			;
		                        		
		                        			Hepatitis C, Chronic/complications/*drug therapy/genetics
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Interferon-alpha/therapeutic use
		                        			;
		                        		
		                        			Liver Cirrhosis/complications/*pathology
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Multivariate Analysis
		                        			;
		                        		
		                        			Odds Ratio
		                        			;
		                        		
		                        			Polyethylene Glycols/therapeutic use
		                        			;
		                        		
		                        			RNA, Viral/analysis
		                        			;
		                        		
		                        			Recombinant Proteins/therapeutic use
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Ribavirin/therapeutic use
		                        			;
		                        		
		                        			Severity of Illness Index
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
8.Clinical and gene study of three pedigrees of phytosterolemia associated with macrothrombocytopenia and hemolysis.
Gai-feng WANG ; Zhao-yue WANG ; Li-juan CAO ; Ming-hua JIANG ; Xiong-hua SUN ; Xia BAI ; Chang-geng RUAN
Chinese Journal of Hematology 2011;32(5):331-336
OBJECTIVETo study the clinical features and ABCG5/ABCG8 gene mutations of three pedigrees of phytosterolemia presented with macrothrombocytopenia and hemolysis.
METHODSErythrocyte and platelet morphology were examined under light microscope. Plasma sterol levels were measured by high pressure/performance liquid chromatography method. All of ABCG5 and ABCG8 exons and intron-exon boundaries were directly sequenced to identify mutations, the corresponding gene mutation sites of three families members and healthy individuals were detected.
RESULTSAll the patients presented macrothrombocytopenia, hemolysis, splenomegaly and xanthomas. The blood smears showed large platelets, some as large as erythrocytes, and abnormal erythrocyte shapes, such as stomatocytes. Plasma concentrations of phytosterols, especially sitosterol were markedly elevated (30 fold) in the affected patients. Four mutations were identified in these three pedigrees, ABCG5 C20896T (R446X) and A20883G, ABCG8 del43683-43724 and del1938C-1939G/ins1938T. The latter three were novel mutations reported for the first time.
CONCLUSIONSPhytosterolemia associated with macrothrombocytopenia and hemolysis is a new subtype of this disease. Plasma phytosterols and related gene analysis should be performed when ever an unexplained macrothrombocytopenia, especially combined with haemolysis or/and stomatocytosis.
ATP Binding Cassette Transporter, Sub-Family G, Member 5 ; ATP Binding Cassette Transporter, Sub-Family G, Member 8 ; ATP-Binding Cassette Transporters ; genetics ; Adult ; Blood Platelets ; cytology ; DNA Mutational Analysis ; Erythrocytes, Abnormal ; Female ; Hemolysis ; genetics ; Humans ; Hypercholesterolemia ; genetics ; pathology ; Intestinal Diseases ; genetics ; pathology ; Lipid Metabolism, Inborn Errors ; genetics ; pathology ; Lipoproteins ; genetics ; Male ; Middle Aged ; Mutation ; Pedigree ; Phytosterols ; adverse effects ; blood ; genetics ; Platelet Count ; Thrombocytopenia ; genetics ; pathology
9.Platelet count of peripheral blood is associated with invasion and metastasis of esophageal carcinoma.
Xin-chun YU ; Shan-shui WU ; Xiao-qing LU ; Li-ming SHENG ; Ya-guo HU ; Jian ZHAO ; Juan-mei LI ; Hai-yan SHAO
Journal of Zhejiang University. Medical sciences 2009;38(2):170-173
OBJECTIVETo analyze the association between the platelet count of peripheral blood and clincopathologic parameters of esophageal carcinoma.
METHODSPlatelets of peripheral blood were measured in 415 cases of esophageal carcinoma and 325 healthy subjects as control. The correlation of platelet counts and clinicopathological features of cancer was analyzed.
RESULTPlatelet count in patients with esophageal carcinomas (286+/-88)x10(9)/L was significantly higher than that in the control subjects [(204+/-114)x10(9)/L, P<0.05 ]. Increased platelet counts (>300 x 10(9)/L) was significantly associated with tumor infiltration and lymph node metastasis in patients with esophageal cancer (P<0.05).
CONCLUSIONPlatelet count of peripheral blood might be associated with the development and progression of esophageal cancer.
Adult ; Aged ; Aged, 80 and over ; Blood Platelets ; cytology ; Carcinoma, Squamous Cell ; blood ; pathology ; Case-Control Studies ; Esophageal Neoplasms ; blood ; pathology ; Female ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Platelet Count
10.Study on platelet activated state and platelet activated function in adults with acute leukemia.
Wen-Da LUO ; Bao-Guo CHEN ; Zhe-Feng MEN ; Bo-Li LI ; Min ZHU ; Qun-Yi GUO
Journal of Experimental Hematology 2005;13(3):452-455
		                        		
		                        			
		                        			To investigate the changes of platelet activated state and platelet activated function by trace whole blood flow cytometry (FCM), and to explore the mechanism of hemorrhage and infiltration in adults with acute leukemia, the expression percentage and changes of these expressions of CD62p and PAC-1 on platelet surface were determined by FCM of trace whole blood after platelet activated by ADP in patients with new diagnosed AL (group I), complete remission (CR, group II) and continuously complete remission (CCR, group III). Healthy adults were used as control group. The result showed that the expression of CD62p in group I and II was higher than that in control group, before and after platelet activated by ADP (P < 0.01). The expression of PAC-1 in group I was higher than that in control group (P < 0.01), the expression of PAC-1 in group II was lower than that in control group (P > 0.01), There was no significant difference in expression of CD62p and PAC-1 between group III and control group (P > 0.01), and no significant difference was found between AL group with megakaryocyte malignant pathological changes and AL group without megakaryocyte malignant pathological changes before platelet activated by ADP (P > 0.01). After platelet activated by ADP, the expression of PAC-1 in the former was lower than that in the latter (P < 0.01). It is concluded that (1) high level activated platelet in peripheral blood of AL patients show that interaction between activated platelet and leukemia cells can be one of reason resulting in widespread hemorrhage and infiltration AL patiens; (2) the decrease of number and activted function of platelet at the first stage of AL patients may be caused by malignant hyperplasia of leukemia cells and damage of megakaryopoiesis in bone marrow.
		                        		
		                        		
		                        		
		                        			Acute Disease
		                        			;
		                        		
		                        			Adenosine Diphosphate
		                        			;
		                        		
		                        			pharmacology
		                        			;
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Blood Platelets
		                        			;
		                        		
		                        			cytology
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Cell Membrane
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			metabolism
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Flow Cytometry
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Leukemia
		                        			;
		                        		
		                        			blood
		                        			;
		                        		
		                        			pathology
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			P-Selectin
		                        			;
		                        		
		                        			biosynthesis
		                        			;
		                        		
		                        			Platelet Activation
		                        			;
		                        		
		                        			drug effects
		                        			;
		                        		
		                        			physiology
		                        			;
		                        		
		                        			Platelet Glycoprotein GPIIb-IIIa Complex
		                        			;
		                        		
		                        			biosynthesis
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail